NEXGEL, Inc. (NASDAQ:NXGL) Short Interest Down 26.6% in April

NEXGEL, Inc. (NASDAQ:NXGL) saw a large decline in short interest during the month of April. As of April 15th, there was short interest totalling 17,700 shares, a decline of 26.6% from the March 31st total of 24,100 shares. Approximately 0.4% of the company’s shares are sold short. Based on an average trading volume of 21,600 shares, the short-interest ratio is currently 0.8 days.

NEXGEL Trading Down 3.3 %

Shares of NASDAQ:NXGL traded down $0.08 during trading on Friday, reaching $2.21. 7,486 shares of the stock were exchanged, compared to its average volume of 16,956. The firm has a market cap of $13.77 million, a price-to-earnings ratio of -3.95 and a beta of 0.68. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.46 and a current ratio of 1.98. NEXGEL has a 12-month low of $1.40 and a 12-month high of $3.14. The firm’s 50-day moving average price is $2.44 and its 200 day moving average price is $2.20.

NEXGEL (NASDAQ:NXGL) last posted its earnings results on Monday, April 1st. The company reported ($0.19) earnings per share for the quarter. NEXGEL had a negative net margin of 77.19% and a negative return on equity of 49.49%. The business had revenue of $1.08 million for the quarter.

Insider Buying and Selling at NEXGEL

In other NEXGEL news, CFO Adam E. Drapczuk III bought 47,394 shares of NEXGEL stock in a transaction that occurred on Friday, March 1st. The shares were purchased at an average cost of $2.11 per share, for a total transaction of $100,001.34. Following the completion of the transaction, the chief financial officer now owns 47,394 shares of the company’s stock, valued at approximately $100,001.34. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CFO Adam E. Drapczuk III bought 47,394 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was purchased at an average cost of $2.11 per share, for a total transaction of $100,001.34. Following the completion of the acquisition, the chief financial officer now owns 47,394 shares in the company, valued at $100,001.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Scott Robert Henry purchased 23,697 shares of the business’s stock in a transaction on Friday, March 1st. The shares were bought at an average cost of $2.11 per share, for a total transaction of $50,000.67. Following the purchase, the director now owns 135,735 shares of the company’s stock, valued at $286,400.85. The disclosure for this purchase can be found here. 27.15% of the stock is currently owned by insiders.

Institutional Investors Weigh In On NEXGEL

An institutional investor recently bought a new position in NEXGEL stock. Northeast Financial Group Inc. purchased a new position in shares of NEXGEL, Inc. (NASDAQ:NXGL) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 11,848 shares of the company’s stock, valued at approximately $32,000. Northeast Financial Group Inc. owned 0.19% of NEXGEL at the end of the most recent reporting period. Hedge funds and other institutional investors own 2.21% of the company’s stock.

About NEXGEL

NEXGEL, Inc manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc and changed its name to NEXGEL, Inc in November 2019.